EK Kruithof

3.1k total citations · 1 hit paper
31 papers, 2.6k citations indexed

About

EK Kruithof is a scholar working on Cancer Research, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, EK Kruithof has authored 31 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cancer Research, 19 papers in Hematology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in EK Kruithof's work include Protease and Inhibitor Mechanisms (23 papers), Blood Coagulation and Thrombosis Mechanisms (19 papers) and Blood properties and coagulation (6 papers). EK Kruithof is often cited by papers focused on Protease and Inhibitor Mechanisms (23 papers), Blood Coagulation and Thrombosis Mechanisms (19 papers) and Blood properties and coagulation (6 papers). EK Kruithof collaborates with scholars based in Switzerland, France and United States. EK Kruithof's co-authors include Paul Declerck, I. Juhan‐Vague, Marie‐Christine Alessi, Margot F. K. Verstreken, Adriana Ransijn, F. Bachmann, Mark S. Baker, F Bachmann, Désiré Collen and Désiré Collen and has published in prestigious journals such as Blood, International Journal of Cancer and Journal of the American Academy of Dermatology.

In The Last Decade

EK Kruithof

29 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay

1988 476 citations Paul Declerck, EK Kruithof et al. Blood profile →

Peers

Countries citing papers authored by EK Kruithof

Since Specialization

Citations

This map shows the geographic impact of EK Kruithof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by EK Kruithof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites EK Kruithof more than expected).

Fields of papers citing papers by EK Kruithof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by EK Kruithof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by EK Kruithof. The network helps show where EK Kruithof may publish in the future.

Co-authorship network of co-authors of EK Kruithof

This figure shows the co-authorship network connecting the top 25 collaborators of EK Kruithof. A scholar is included among the top collaborators of EK Kruithof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with EK Kruithof. EK Kruithof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Human tissue-type plasminogen activator 2014 ·Thrombosis and Haemostasis ·EK Kruithof, Sylvie Dunoyer-Geindre	44
2	Ex vivo Pulsatile Perfusion of Human Saphenous Veins Induces Intimal Hyperplasia and Increased Levels of the Plasminogen Activator Inhibitor 1 2010 ·European Surgical Research ·François Saucy, (unknown), Florian Alonso, Xavier Bérard, Sébastien Déglise, Sylvie Dunoyer-Geindre, Lucia Mazzolai, EK Kruithof, Jacques‐Antoine Haefliger, Jean-Marc Corpataux	14
3	Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model 2008 ·Cancer Gene Therapy ·(unknown), Richard J. Fish, (unknown), (unknown), EK Kruithof, Benoı̂t Polack, Gilles Pernod	9
4	Retinoids and activation of PKC induce tissue‐type plasminogen activator expression and storage in human astrocytes 2008 ·Journal of Thrombosis and Haemostasis ·Karin Hultman, Anna Tjärnlund‐Wolf, Richard J. Fish, Ulrika Wilhelmsson, Bertil Rydenhag, Milos Pekny, EK Kruithof, Christina Jern	8
5	Effects of statins on adhesion molecule expression in endothelial cells 2003 ·Journal of Thrombosis and Haemostasis ·(unknown), Sylvie Dunoyer-Geindre, Guido Reber, François Mach, EK Kruithof, Philippe de Moerloose	27
6	Fibrinolytic abnormalities in two different cutaneousmanifestations of venous disease 1996 ·Journal of the American Academy of Dermatology ·David J. Margolis, EK Kruithof, (unknown), Keith Howe, Gerald S. Lazarus	16
7	Biological evaluation of the fibrinolytic system 1993 ·Fibrinolysis and Proteolysis ·EK Kruithof	5
8	The plasminogen‐activation system in ovarian tumors 1993 ·International Journal of Cancer ·Éric Pujade-Lauraine, Lu H, (unknown), J. Soria, Claudine Soria, A Bernadou, EK Kruithof, H.R. Lijnen, P Burtin	49
9	Partial characterisation of a plasminogen activator inhibitor 1 stimulating factor produced by human hepatoma cells 1993 ·Fibrinolysis and Proteolysis ·Gabriela E. Bergonzelli, EK Kruithof	2
10	Plasma levels of plasminogen activator inhibitor type 1, beta- thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase 1991 ·Blood ·(unknown), V. Grimaudo, Paul Declerck, EK Kruithof, F. Bachmann	37
11	A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1 1991 ·Blood ·J Diéval, G. Nguyen, Sylvie Gross, J Delobel, EK Kruithof	115
12	A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1 1991 ·Blood ·J Diéval, G. Nguyen, Sylvie Gross, J Delobel, EK Kruithof	3
13	Plasma levels of plasminogen activator inhibitor type 1, beta- thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase 1991 ·Blood ·(unknown), V. Grimaudo, Paul Declerck, EK Kruithof, F Bachmann	1
14	Antigen Levels of Plasminogen Activator Inhibitor Type 1 in Citrated Plasma: Determination of the Contribution of Platelets 1990 ·Pathophysiology of Haemostasis and Thrombosis ·V. Grimaudo, F Bachmann, EK Kruithof	3
15	Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis 1988 ·Blood ·Giang Huong Nguyen, MH Horellou, EK Kruithof, J Conard, (unknown)	53
16	Fibrinolytic and Anticoagulant Activity After a Single Subcutaneous Administration of a Low Dose of Heparin or a Low Molecular Weight Heparin-Dihydroergotamine Combination 1988 ·Thrombosis and Haemostasis ·V. Grimaudo, Abdelwahab Omri, EK Kruithof, J Hauert, F Bachmann	11
17	Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors 1987 ·Blood ·EK Kruithof, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	19
18	Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation 1987 ·Blood ·EK Kruithof, (unknown), (unknown)	12
19	Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma 1984 ·Blood ·EK Kruithof, (unknown), Adriana Ransijn, F. Bachmann	331
20	Influence of detergents on the measurement of the fibrinolytic activity of plasminogen activators 1982 ·Thrombosis Research ·EK Kruithof, Adriana Ransijn, F Bachmann	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact